Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Traumatic Brain Injury
Interventions: Aerobic Exercise (AER), Rehabilitation; Other
Lead sponsor: Centre for Neuro Skills; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Plantar Fasciitis
Interventions: Topical oil application; Other
Lead sponsor: Center for Biomedical Research, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Pancreatic Cancer
Interventions: ABBV-927, Budiglimab, modified FOLFIRINOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: RSV
Interventions: zelicapavir, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Cape Coral, Florida • Miami, Florida • Bluffton, South Carolina + 1 more

Conditions: Coronary Artery Disease, Peripheral Vascular Disease
Interventions: SafeSeal(TM) Hemostasis Patch; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Plaque Psoriasis
Interventions: E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 16
States / cities: Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Metformin DR, Metformin IR, Metformin DR Placebo, Metformin IR placebo; Drug
Lead sponsor: Anji Pharma; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 33
States / cities: Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions: Ravulizumab, BSC; Biological · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more

Conditions: Macular Degeneration
Interventions: rhuFab V2 (ranibizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 70
States / cities: Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more

Conditions: Sexual Violence
Interventions: Online Bystander Training, Online Substance Abuse Training, In-Person Bystander Training, In-Person Combination Training; Behavioral
Lead sponsor: Heather Bush; Other
Eligibility: 17 Years to 24 Years
Enrollment: 3,178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Burns
Interventions: AWBAT Wound Dressing, AWBAT™, Biobrane®; Device
Lead sponsor: Aubrey Inc.; Industry
Eligibility: 1 Year to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 3
States / cities: Irvine, California • Columbia, Missouri • Galveston, Texas

Conditions: Appendicitis
Interventions: UGBRSB, Local Infiltration; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Keratoconus, Dry Eye, Allergy
Interventions: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly; Drug
Lead sponsor: Illinois College of Optometry; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Differential Diagnosis, Diagnostic Accuracy
Interventions: AI Diagnostic System (AIMD.1); Diagnostic Test
Lead sponsor: Magic Health Inc. (d.b.a. Nolla Health); Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: EGT0001442, Placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Buena Park, California • Los Angeles, California • Santa Ana, California + 8 more

Conditions: Kidney Transplantation
Interventions: TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG; Biological · Drug
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • Kansas City, Kansas • Boston, Massachusetts + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more

Conditions: Hemorrhage
Interventions: TachoSil, Surgicel Original; Biological
Lead sponsor: Corza Medical GmbH; Industry
Eligibility: 1 Month and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Torrance, California • Lakewood, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: OSA
Interventions: AD109, Placebo; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 65
States / cities: Tuscaloosa, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: COPD
Interventions: Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Deep Dental Caries
Interventions: Indirect Pulp capping-Resin-modified calcium silicate - TheraCal, Indirect Pulp capping-Calcium hydroxide - Dycal, Indirect Pulp capping-Resin-based dentin bonding agent, Direct Pulp capping-Resin-modified calcium silicate - TheraCal, Direct Pulp capping-Calcium hydroxide - Dycal; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myoma
Interventions: Vasopressins; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 2
States / cities: Beachwood, Ohio • Cleveland, Ohio

Search by objective public record fields.

Aerobic Exercise After Traumatic Brain Injury

Topical Phytoterpenes for Plantar Fasciitis

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease

Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Tiotropium/Salmeterol Inhalation Powder in COPD

Investigational Study of Delayed Release Metformin

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

ConnectEd: A Randomized Controlled Trial Connecting Through Educational Training

A Postmarket Randomized Study of the Treatment of Superficial Partial-Thickness Burns Using Two Dressings

A Comparison of UGBRS Block and Local Infiltration

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

A Dose Escalation Study in de Novo Renal Transplantation

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

Clinical Comparison of Vital Pulp Capping Restorative Protocols

Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy